These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22357256)

  • 1. Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    Oonk AMM; van Rijn C; Smits MM; Mulder L; Laddach N; Savola SP; Wesseling J; Rodenhuis S; Imholz ALT; Lips EH
    Ann Oncol; 2012 Sep; 23(9):2301-2305. PubMed ID: 22357256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
    Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
    Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC
    Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
    Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
    Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
    Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
    PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
    de Boo LW; Jóźwiak K; Joensuu H; Lindman H; Lauttia S; Opdam M; van Steenis C; Brugman W; Kluin RJC; Schouten PC; Kok M; Nederlof PM; Hauptmann M; Linn SC
    Br J Cancer; 2022 Jun; 126(10):1401-1409. PubMed ID: 35124703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
    JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
    van Rossum AGJ; Schouten PC; Weber KE; Nekljudova V; Denkert C; Solbach C; Köhne CH; Thomssen C; Forstbauer H; Hoffmann G; Kohls A; Schmatloch S; Schem C; von Minckwitz G; Karn T; Möbus VJ; Linn SC; Loibl S; Marmé F
    Breast Cancer Res Treat; 2017 Dec; 166(3):775-785. PubMed ID: 28822007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
    Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
    Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Colleoni M; Cole BF; Viale G; Regan MM; Price KN; Maiorano E; Mastropasqua MG; Crivellari D; Gelber RD; Goldhirsch A; Coates AS; Gusterson BA
    J Clin Oncol; 2010 Jun; 28(18):2966-73. PubMed ID: 20458051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy.
    Schouten PC; Marmé F; Aulmann S; Sinn HP; van Essen HF; Ylstra B; Hauptmann M; Schneeweiss A; Linn SC
    Clin Cancer Res; 2015 Feb; 21(4):763-70. PubMed ID: 25480832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
    Schouten PC; Gluz O; Harbeck N; Mohrmann S; Diallo-Danebrock R; Pelz E; Kruizinga J; Velds A; Nieuwland M; Kerkhoven RM; Liedtke C; Frick M; Kates R; Linn SC; Nitz U; Marme F
    Int J Cancer; 2016 Aug; 139(4):882-9. PubMed ID: 26946057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
    Rais G; Raissouni S; Aitelhaj M; Rais F; Naciri S; Khoyaali S; Abahssain H; Bensouda Y; Khannoussi B; Mrabti H; Errihani H
    BMC Womens Health; 2012 Oct; 12():35. PubMed ID: 23039971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.